WORLDWIDE HEALTH SCIENCES PORTFOLIO
NSAR-B, EX-27, 2000-10-04
Previous: WORLDWIDE HEALTH SCIENCES PORTFOLIO, NSAR-B, 2000-10-04
Next: INTROGEN THERAPEUTICS INC, S-1/A, 2000-10-04



<TABLE> <S> <C>

<ARTICLE> 6
<MULTIPLIER> 1000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          AUG-31-1999
<PERIOD-END>                               AUG-31-1999
<INVESTMENTS-AT-COST>                           160438
<INVESTMENTS-AT-VALUE>                          202733
<RECEIVABLES>                                      202
<ASSETS-OTHER>                                    2154
<OTHER-ITEMS-ASSETS>                                 6
<TOTAL-ASSETS>                                  205096
<PAYABLE-FOR-SECURITIES>                             0
<SENIOR-LONG-TERM-DEBT>                              0
<OTHER-ITEMS-LIABILITIES>                           15
<TOTAL-LIABILITIES>                                 15
<SENIOR-EQUITY>                                      0
<PAID-IN-CAPITAL-COMMON>                        162784
<SHARES-COMMON-STOCK>                                0
<SHARES-COMMON-PRIOR>                                0
<ACCUMULATED-NII-CURRENT>                            0
<OVERDISTRIBUTION-NII>                               0
<ACCUMULATED-NET-GAINS>                              0
<OVERDISTRIBUTION-GAINS>                             0
<ACCUM-APPREC-OR-DEPREC>                         42297
<NET-ASSETS>                                    205081
<DIVIDEND-INCOME>                                  873
<INTEREST-INCOME>                                   26
<OTHER-INCOME>                                       0
<EXPENSES-NET>                                    1684
<NET-INVESTMENT-INCOME>                          (784)
<REALIZED-GAINS-CURRENT>                         19259
<APPREC-INCREASE-CURRENT>                        57606
<NET-CHANGE-FROM-OPS>                            76081
<EQUALIZATION>                                       0
<DISTRIBUTIONS-OF-INCOME>                            0
<DISTRIBUTIONS-OF-GAINS>                             0
<DISTRIBUTIONS-OTHER>                                0
<NUMBER-OF-SHARES-SOLD>                              0
<NUMBER-OF-SHARES-REDEEMED>                          0
<SHARES-REINVESTED>                                  0
<NET-CHANGE-IN-ASSETS>                           60418
<ACCUMULATED-NII-PRIOR>                              0
<ACCUMULATED-GAINS-PRIOR>                            0
<OVERDISTRIB-NII-PRIOR>                              0
<OVERDIST-NET-GAINS-PRIOR>                           0
<GROSS-ADVISORY-FEES>                             1142
<INTEREST-EXPENSE>                                  23
<GROSS-EXPENSE>                                   1799
<AVERAGE-NET-ASSETS>                            186537
<PER-SHARE-NAV-BEGIN>                                0
<PER-SHARE-NII>                                      0
<PER-SHARE-GAIN-APPREC>                              0
<PER-SHARE-DIVIDEND>                                 0
<PER-SHARE-DISTRIBUTIONS>                            0
<RETURNS-OF-CAPITAL>                                 0
<PER-SHARE-NAV-END>                                  0
<EXPENSE-RATIO>                                   0.90


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission